跳转至内容
Merck

53541

Supelco

妥布特罗 盐酸盐

VETRANAL®, analytical standard

别名:

2-叔丁氨基-1-(2-氯苯基)乙醇 盐酸盐

登录查看公司和协议定价

选择尺寸

10 MG
$656.00

$656.00


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
10 MG
$656.00

About This Item

经验公式(希尔记法):
C12H18ClNO · HCl
CAS号:
分子量:
264.19
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

$656.00


请联系客服了解存货情况

获取大包装报价

等级

analytical standard

质量水平

产品线

VETRANAL®

方案

≥98.0% (HPLC)

技术

HPLC: suitable
gas chromatography (GC): suitable
solid phase extraction (SPE): suitable

应用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

包装形式

neat

储存温度

2-8°C

SMILES字符串

Cl.CC(C)(C)NCC(O)c1ccccc1Cl

InChI

1S/C12H18ClNO.ClH/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13;/h4-7,11,14-15H,8H2,1-3H3;1H

InChI key

RSLNRVYIRDVHLY-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

Supelco MIP SPE柱的标准品。有关更多信息,请索要Supelco文献T407075、T706019、T706030、T706020
盐酸妥洛特罗是一种拟交感神经胺,具有支气管扩张剂的活性。[1]

应用

有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务。
盐酸妥洛特罗可作为参考标准品,通过气相色谱-串联质谱(GC-MS-MS)测定牛肝匀浆和尿液样品中盐酸妥洛特罗的浓度。[2]

包装

无底玻璃瓶。内含物在插入的融合锥体内。

法律信息

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ki-Seok Kim et al.
Colloids and surfaces. B, Biointerfaces, 92, 240-245 (2011-12-30)
Porous poly(ε-caprolactone) (PCL)/Eudragit RS 100 (ERS-100) microcapsules containing tulobuterol-adsorbed silica nanotubes (S-NTs) were prepared using a solvent evaporation method. The release behaviors of the PCL/ERS-100 microcapsules were investigated as a function of S-NT content. The PCL/ERS-100 microcapsules showed a stable
Determination of tulobuterol in human plasma by capillary gas chromatography
Wood G S and Chasseaud F L.
Journal of Chromatography. B, Biomedical Sciences and Applications, 416, 154-159 (1987)
Masakazu Ichinose et al.
Respiratory medicine, 104(2), 267-274 (2009-10-31)
The current mainstream treatment for COPD is bronchodilators alone or in combination. The effects of a beta(2)-agonist, tulobuterol, administered transdermally, have been reported to last for 24h. However, there are no reports on the efficacy of tulobuterol combined with an
Gen Tamura et al.
Allergology international : official journal of the Japanese Society of Allergology, 61(2), 219-229 (2012-01-25)
Tulobuterol patch (HokunalinTM Tape), which contains a β(2)-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides
Masashi Kanehara et al.
Pulmonary pharmacology & therapeutics, 21(6), 874-878 (2008-11-06)
The airway inflammation of chronic obstructive pulmonary disease (COPD) demonstrates a poor response to the anti-inflammatory actions of corticosteroids. However, long-acting beta(2)-agonists and low-dose theophylline are reported to have a possible anti-inflammatory effect in COPD. The aim of this study

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门